ETFChannel.com
GNVC Description — GenVec Inc (DE)

GenVec is a clinical-stage biopharmaceutical company with a focus on utilizing its proprietary AdenoVerse™ gene delivery platform to develop a pipeline of therapeutics and vaccines. Co. is engaged in the design, testing and manufacture of adenoviral-based product candidates. Co.'s key product candidate, CGF166, is in a clinical study for the treatment of hearing loss and balance disorders. Co.'s combination of internal and partnered development programs address therapeutic areas, as well as vaccines against infectious diseases, including respiratory syncytial virus, herpes simplex virus, and malaria. In the area of animal health, Co. is developing vaccines against foot-and-mouth disease.

Company Name: 
GenVec Inc (DE)
Website: 
www.genvec.com
Sector: 
Biotechnology
Quotes delayed 20 minutes

Email EnvelopeFree GNVC Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Hold (2.00 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com

ETFs Holding GNVC | GenVec Inc (DE) | ETF Channel | www.ETFChannel.com

Copyright © 2010 - 2024, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.